Thank you for your interest in this study.  The purpose of the research is to speak with patients who have primary liver cancer (also known as hepatocellular carcinoma or HCC) to better understand the signs, symptoms, and impacts they are experiencing, and to get reactions to a questionnaire designed to assess patient with your condition.  Please answer the following eligibility questions to see if you can take part in an interview.  For eligible respondents, the research will be a 75 to 90-minute telephone interview. If you qualify and participate in the study, you will receive compensation for your time.

Any information you provide to us as part of the eligibility questions will be treated as confidential.  Your responses will be combined with feedback from others like yourself and will be stored in accordance to our privacy policies. We will keep your information secure at all times. You will remain anonymous at all times and your information will not be passed to any other organization without your permission.

This research is being conducted by IQVIA on behalf of a pharmaceutical sponsor.

If you qualify for the study after completing this survey, you will be redirected to fill out a separate online consent form that provides more information on the study, your role in the study, compensation for your time, and your rights.

You have the right to withdraw at any time.  For more information about your rights, please see our privacy notice, which is available at www.iqvia.com/about-us/privacy.

If you have any questions, please contact Farah Toublan at Farah.Toublan@IQVIA.com or phone 929-270-8125.